Skip to main content

Advertisement

Table 5 Safety profile of rheumatoid arthritis treatment

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Side effect CHB group (n = 32) Non-CHB group (n = 128) p valuea
Total side effects, n (%) 15 (47) 68 (53) 0.572
Infections 5 (16) 16 (13) 0.676
Gastrointestinal discomfort 7 (22) 22 (17) 0.583
Trichomadesis 2 (6) 13 (10) 0.547
Neutropenia 2 (6) 14 (11) 0.484
Aminotransferase elevation 6 (19) 39 (30) 0.244
  < two fold ULN 4 (13) 30 (23) 0.234
  ≥ two fold, < three fold ULN 1 (3) 7 (6) 0.630
  ≥ three fold ULN 1 (3) 2 (2) 0.606
Antiviral prophylaxis 14 (44) 0 (0) NA
HBV reactivation 11 (34) 0 (0) NA
 Antiviral prophylaxis (+) 3 (9) 0 (0) NA
 Antiviral prophylaxis (−) 8 (25) 0 (0) NA
  1. CHB chronic HBV infection, HBV hepatitis B virus, NA not applicable, ULN upper limit of the normal range
  2. aCompared between the CHB group and the non-CHB group using conditional logistic regression analysis